A Phase 2a Study of Simtuzumab in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis



Status:Completed
Conditions:HIV / AIDS, Gastrointestinal, Hepatitis
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:August 2012
End Date:October 2014

Use our guide to learn which trials are right for you!

A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis

This is an open label, exploratory study of simtuzumab (GS-6624) in adults infected with
HIV, hepatitis C virus (HCV), or co-HIV/HCV with histological evidence of liver fibrosis.
Participants will receive simtuzumab 700 mg intravenously every 2 weeks for a total of 24
weeks (12 infusions) while continuing on standard therapy for HIV (HIV-infected subjects
only).


Key Inclusion Criteria:

- HIV-infected subjects must have positive serologies with viral load suppressed below
400 copies/mL

- HCV-infected subjects must have:

- Chronic HCV infection with HCV RNA ≥ 2000 IU/ml AND at least 1 of the following:

- Been null responder to previous pegylated interferon and ribavirin therapy OR

- Failed to achieve sustained virologic response (SVR) on a regimen containing a
direct-acting antiviral (DAA) in addition to pegylated interferon and ribavirin
OR

- Are unwilling to receive or have contraindications to interferon therapy for HCV

- HIV/HCV co-infected subjects must have:

- Positive HIV serologies with viral load suppressed below 400 copies/mL

- Chronic HCV infection with HCV RNA ≥ 2000 IU/ml AND at least 1 of the following:

- Been null responder to previous pegylated interferon and ribavirin therapy OR

- Failed to achieve SVR on a regimen containing a direct-acting antiviral (DAA) in
addition to pegylated interferon and ribavirin OR

- Are unwilling to receive or have contraindications to interferon therapy for HCV

- Willing to allow blood and tissue samples to be stored for future use to study HIV
infection, immune function, liver disease and additional mechanisms involved in liver
fibrosis among patients with HIV and/or HCV, which may not be related directly to the
specific objectives of this study protocol

- Have a primary care physician

Key Exclusion Criteria:

- Cause of liver fibrosis other than HCV or long-term ART treatment for HIV

- Currently being treated for HCV

- Evidence of active Hepatitis A, B or D infections

- History or evidence of hepatocellular carcinoma

- Unwillingness to undergo a liver biopsy pre-treatment and post-treatment, or to
undergo all other protocol required tests/procedures or return to the site for
required visits

- Presence of contraindications to magnetic resonance imaging (e.g., presence of any
metal in the body, cardiac or neural pacemaker, aneurysm clip, cochlear implant,
claustrophobia)
We found this trial at
1
site
Bethesda, Maryland 20892
?
mi
from
Bethesda, MD
Click here to add this to my saved trials